Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment

Diabetes, Obesity & Metabolism
F Javier EscaladaRobert Ritzel

Abstract

To investigate the impact of renal function on the safety and efficacy of insulin glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m2 . The decrease in glycated haemoglobin (HbA1c) after 6 months and the proportion of individuals with T2DM achieving HbA1c targets were similar in the Gla-300 and Gla-100 groups, for both renal function subgroups. There was a reduced risk of nocturnal (12:00-5:59 am) confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 in both renal function subgroups (eGFR <60 mL/min/1.73 m2 : relative risk [RR] 0.76 [95% confidence interval {CI} 0.62-0.94] and eGFR ≥60 mL/min/1.73 m2 : RR 0.75 [95% CI 0.67-0.85]). For confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycaemia at any time of day (24 hours) the hypoglycaemia risk was lower with Gla-300 vs Gla-100 in both the lower (RR 0...Continue Reading

References

Apr 28, 2005·Diabetes Care·UNKNOWN Workgroup on Hypoglycemia, American Diabetes Association
Dec 23, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Amanda D HyrePaul Muntner
May 9, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Maureen F MoenJeffrey C Fink
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Oct 17, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN National Kidney Foundation
Mar 20, 2014·Kidney & Blood Pressure Research·Kosaku NittaSusumu Takahashi
Sep 27, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Katherine R TuttleMark E Molitch
Aug 5, 2015·Journal of Clinical Medicine·Mazen Alsahli, John E Gerich
Mar 2, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Rajiv SaranRichard A Hirth

❮ Previous
Next ❯

Citations

Jul 3, 2019·Diabetes, Obesity & Metabolism·Timothy S BaileyLawrence Blonde
Apr 22, 2020·World Journal of Diabetes·Sujoy Ghosh, Romik Ghosh
Nov 30, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Pierre GourdyBruno Guerci
Sep 26, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Alice Y Y ChengElif Ekinci
Mar 23, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Didac MauricioDirk Müller-Wieland
Aug 28, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·David León-JiménezJavier Escalada-San Martín
Nov 3, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·John AndersonParesh Dandona
Jan 27, 2022·Diabetic Medicine : a Journal of the British Diabetic Association·Janaka KarallieddeStephen C Bain

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01499082
NCT01499095
NCT01676220

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved